Chong Kun Dang Pharmaceutical: Essential Hypertension trials

The registry lists 11 Essential Hypertension studies with Chong Kun Dang Pharmaceutical as lead sponsor. 2 are open to participants now and 0 have results posted.

Phase 1 3Phase 2 1Phase 3 5Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202ARecruitingNCT06643819Phase 3
• A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic SyndromeNot yet recruitingNCT05843162Phase 4
• Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 MonotherapyCompletedNCT06121518Phase 3
• Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination TherapyCompletedNCT05931224Phase 3
• Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination TherapyStatus unknownNCT05526703Phase 3
• Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension, Chronic Stable Angina and Congestive Heart FailureStatus unknownNCT03063697
• A Dose Selection Trial of CKD-330 in Patients With Essential HypertensionStatus unknownNCT02206165Phase 2
• Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.CompletedNCT01842256Phase 1
• Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipineCompletedNCT01842230Phase 1
• Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mgStatus unknownNCT01819870Phase 1
• Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential HypertensionCompletedNCT01756430Phase 3